Targeting angiogenesis in metastatic renal cell carcinoma

References

• Medina-Rico M, Ramos HL, Lobo M, et al. Epidemiology of renal cancer in developing countries: review of the literature. Can Urol Assoc J. 2018 Mar;12(3):E154. PubMed PMID: 29283089; PubMed Central PMCID: PMCPMC5869042.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010. [Based on the November 2012 SEER data submission, posted to the SEER web site, April 2013.]. Bethesda, MD: National Cancer Institute. (2013; 9).
   Google Scholar
• Jonasch E, Gao J, Rathmell WK. State of the art review: renal cell carcinoma. BMJ. 2014;349, g4797.
   Google Scholar
• Wong MCS, Goggins WB, Yip BHK, et al. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci Rep. 2017;7(1):15698.
   PubMedGoogle Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–621.
   PubMed Web of Science ®Google Scholar
• Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010 May;7(5):245–257. PubMed PMID: 20448658; PubMed Central PMCID: PMCPMC3012455.
   PubMed Web of Science ®Google Scholar
• Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008 Aug 1;14(15):4726–4734. PubMed PMID: 18676741; PubMed Central PMCID: PMCPMC2629664.
   PubMed Web of Science ®Google Scholar
• Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J clin oncol. 2014 Jun 20;32(18):1968. PubMed PMID: 24821879; PubMed Central PMCID: PMCPMC4050206.
   PubMed Web of Science ®Google Scholar
• Sanchez DJ, Simon MC. Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochim Biophys Acta (BBA)- Rev Cancer. 2018 Aug;1870(1):23–31. PubMed PMID: 29959988.
   PubMed Web of Science ®Google Scholar
• Cho H, Kaelin WG editors. Targeting HIF2 in clear cell renal cell carcinoma. Cold Spring Harb Symp Quant Biol. 2016;81:113–121. Cold Spring Harbor Laboratory Press.
   PubMedGoogle Scholar
• Semenza GL. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002 Sep;64(5–6):993–998. PubMed PMID: 12213597.
   PubMed Web of Science ®Google Scholar
• Irwin DC, McCord JM, Nozik-Grayck E, et al. A potential role for reactive oxygen species and the HIF-1α–VEGF pathway in hypoxia-induced pulmonary vascular leak. Free Radic Biol Med. 2009;47(1):55–61.
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 2001 Jun;11(3):293–299. PubMed PMID: 11377966.
   PubMed Web of Science ®Google Scholar
• Shen C, Beroukhim R, Schumacher S, et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Dis. 2011: CD-11-0098.
   Web of Science ®Google Scholar
• Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12(1):9.
   Web of Science ®Google Scholar
• Mitchell TJ, Rossi SH, Klatte T, et al. Genomics and clinical correlates of renal cell carcinoma. World J Urol. 2018 Aug, 36(12), 1899-1911. PubMed PMID: 30099580.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat Genet. 2013 Aug;45(8):849. PubMed PMID: 23892664.
   PubMed Web of Science ®Google Scholar
• Lee H, Dai F, Zhuang L, et al. BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21. Oncotarget. 2016;7(15):19134.
   PubMedGoogle Scholar
• Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Sep 1;32(25):2765–2772. PubMed PMID: 25049330; PubMed Central PMCID: PMCPMC5569681.
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Chen D, Wang PI, et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur Urol. 2017;71(3):405–414.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64. PubMed PMID: 24782981; PubMed Central PMCID: PMCPMC3995050.
   PubMedGoogle Scholar
• Conciatori F, Bazzichetto C, Falcone I, et al. Role of mTOR signaling in tumor microenvironment: an overview. Int J Mol Sci. 2018 Aug 19;19;8:2453. PubMed PMID: 30126252; PubMed Central PMCID: PMCPMC6121402.
   Web of Science ®Google Scholar
• Farhan MA, Carmine-Simmen K, Lewis JD, et al. Endothelial cell mTOR complex-2 regulates sprouting angiogenesis. PloS One. 2015;10(8):e0135245. PubMed PMID: 26295809; PubMed Central PMCID: PMCPMC4546419.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I. Sorafenib rechalenge in metastatic renal cell carcinoma. BJU Int. 2012 Sep;110(6b):E235–E235. PubMed PMID: 22332769.
   PubMed Web of Science ®Google Scholar
• Voss MH, Hakimi AA, Pham CG, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res. 2014, 20(7); 1–10.
   PubMedGoogle Scholar
• Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016 May 15;22(10):2445–2452. PubMed PMID: 26831717; PubMed Central PMCID: PMCPMC4976069.
   PubMed Web of Science ®Google Scholar
• Voss MH, Chen D, Reising A, et al. PTEN expression, not mutation status for TSC1, TSC2 or mTOR, correlates with outcome on everolimus in patients with renal cell carcinoma treated on RECORD-3. Clin Cancer Res. 2018. clincanres-1833.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Vida A, Hutson TE, Bellmunt J, et al. New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017;2(2):e000185.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl_3):iii49–iii56.
   PubMedGoogle Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015 May;67(5):913–924. PubMed PMID: 25616710.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017 Jun;15(6):804–834. PubMed PMID: 28596261.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 Dec 22;370(9605):2103–2111. PubMed PMID: 18156031.
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20;26(33):5422. PubMed PMID: 18936475; PubMed Central PMCID: PMCPMC2651074.
   PubMed Web of Science ®Google Scholar
• Bracarda S, Bellmunt J, Melichar B, et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011;107(2):214–219.
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–2150.
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1;28(13):2137. PubMed PMID: 20368558; PubMed Central PMCID: PMCPMC2860433.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115–124. PubMed PMID: 17215529.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277–1290. PubMed PMID: 29562145; PubMed Central PMCID: PMCPMC5972549.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125–134. PubMed PMID: 17215530.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10;27(20):3312–3318. PubMed PMID: 19451442.
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760–767.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 Feb 20;28(6):1061–1068. PubMed PMID: 20100962.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722–731. PubMed PMID: 23964934.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014 May 10;32(14):1412–1418. PubMed PMID: 24687826.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931–1939. PubMed PMID: 22056247; eng.
   PubMed Web of Science ®Google Scholar
• Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14(13):1287–1294.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814–1823. PubMed PMID: 26406150; PubMed Central PMCID: PMCPMC5024539.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927. PubMed PMID: 27279544.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–597.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–125.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–3799.
   PubMed Web of Science ®Google Scholar
• Garnick MB. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study. J Clin Oncol. 2013.
   PubMed Web of Science ®Google Scholar
• Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008 Sep 1;14(17):5459–5465. PubMed PMID: 18765537.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013 Oct 28;340(1):97–103. PubMed PMID: 23856031.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16(15):1473–1482. PubMed PMID: 26482279.
   PubMed Web of Science ®Google Scholar
• Porta C, Sabbatini R, Procopio G, et al. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther. 2012 Dec;12(12):1571–1577. PubMed PMID: 23181412.
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Mans LA, de Graaf AMA, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. 2012 Jul 15;18(14):3961–3971. PubMed PMID: 22573349; PubMed Central PMCID: PMCPMC4015630.
   PubMed Web of Science ®Google Scholar
• Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006 Oct;116(10):2610–2621. PubMed PMID: 17016557; PubMed Central PMCID: PMCPMC1578604.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Fuh KC, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Nat Acad Sci. 2014;111(37):13373–13378.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2012;24(2):343–349.
   PubMed Web of Science ®Google Scholar
• Brodaczewska KK, Szczylik C, Kieda C. Immune consequences of anti-angiogenic therapyin renal cell carcinoma. J Oncol. 2018 Mar;22(1A):14. PubMed PMID: 29628789; PubMed Central PMCID: PMCPMC5885083.
   Google Scholar
• Lee GR. Phenotypic and functional properties of tumor-infiltrating regulatory T cells. Mediators Inflamm. 2017;2017:5458178. PubMed PMID: 29463952; PubMed Central PMCID: PMCPMC5804416.
   PubMedGoogle Scholar
• Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523.
   PubMed Web of Science ®Google Scholar
• Giallongo C, Tibullo D, Parrinello NL, et al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget. 2016 Dec 27;7(52):85764. PubMed PMID: 26967390; PubMed Central PMCID: PMCPMC5349872.
   PubMedGoogle Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162.
   PubMed Web of Science ®Google Scholar
• Sevko A, Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer. 2013;4(1):3.
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008 Jul 1;68(13):5439–5449. PubMed PMID: 18593947; PubMed Central PMCID: PMCPMC2887390.
   PubMed Web of Science ®Google Scholar
• Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer. 2012 Apr 15;130(8):1948–1959. PubMed PMID: 21633954; PubMed Central PMCID: PMCPMC3232304.
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013 Jan 15;73(2):539–549. PubMed PMID: 23108136; eng.
   PubMed Web of Science ®Google Scholar
• Chen ML, Yan BS, Lu WC, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer. 2014 Jan 15;134(2):319–331. PubMed PMID: 23818246; eng.
   PubMed Web of Science ®Google Scholar
• Cabrera R, Ararat M, Xu Y, et al. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2013 Apr;62(4):737–746. PubMed PMID: 23223899; PubMed Central PMCID: PMCPMC3863727. eng.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (New York, NY). 2005 Jan 7;307(5706):58–62. PubMed PMID: 15637262; eng.
   Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001 Sep;7(9):987–989. PubMed PMID: 11533692; eng.
   PubMed Web of Science ®Google Scholar
• Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011 Jul;91(3):1071–1121. PubMed PMID: 21742796; PubMed Central PMCID: PMCPMC3258432. eng.
   PubMed Web of Science ®Google Scholar
• Dirkx AE, Oude Egbrink MG, Castermans K, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006 Apr;20(6):621–630. PubMed PMID: 16581970; eng.
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Damen CA, Blijham GH, et al. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 1996 Jul 15;88(2):667–673. PubMed PMID: 8695814; eng.
   PubMed Web of Science ®Google Scholar
• Messai Y, Gad S, Noman MZ, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol. 2016 Oct;70(4):623–632. PubMed PMID: 26707870; eng.
   PubMed Web of Science ®Google Scholar
• Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J clin oncol. 2014;32(15_suppl):5010.
   Google Scholar
• McDermott DF, Atkins MB, Motzer RJ, et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). J clin oncol. 2017;35(6_suppl):431.
   Web of Science ®Google Scholar
• Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated Metastatic Renal Cell Carcinoma (mRCC). J Clin Oncol. 2018;36(6_suppl):578.
   Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen JBAG, et al. LBA6_PRJAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann Oncol. 2018;29(suppl_8):mdy424.036-mdy424.036.
   Google Scholar
• [cited 2018 Oct 30]. https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pfizers-Inlyta-axitinib-Significantly-Improved-Overall-Survival-OS-and-Progression-free-Survival-PFS-as-First-Line-Therapy-for-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx
   Google Scholar
• Motzer RJ, Grünwald V, Hutson TE, et al. A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2017.
   PubMedGoogle Scholar
• Schödel J, Grampp S, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69(4):646–657. PubMed PMID: 26298207; PubMed Central PMCID: PMCPMC5012644.
   PubMed Web of Science ®Google Scholar
• Courtney KD, Infante JR, Lam ET, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol. 2018 Mar 20;36(9):867–874. PubMed PMID: 29257710; PubMed Central PMCID: PMCPMC5946714.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–790.
   PubMed Web of Science ®Google Scholar
• Barsoum IB, Koti M, Siemens DR, et al. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res. 2014 Dec 15;74(24):7185–7190. PubMed PMID: 25344227.
   PubMed Web of Science ®Google Scholar
• Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016 Jul 15;139(2):396–403. PubMed PMID: 26945902.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol. 2006 Jan 1;24(1):1–3. PubMed PMID: 16330665.
   PubMed Web of Science ®Google Scholar